DR. SHUO MA M.D. PH.D. NPI 1659564938

NPI Details

DR. Shuo Ma, M.D., PH.D. is a hematology and oncology internal medicine in Chicago, IL with 31 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Shuo Ma, M.D., PH.D. NPI is 1659564938. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

676 N SAINT CLAIR ST
SUITE 850
CHICAGO, IL
ZIP 60611-927
Phone: (312) 695-6180
Fax: (312) 695-6189

The NPI 1659564938 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, carfilzomib, 1 mg (HCPCS:J9047)
• Injection, daratumumab, 10 mg (HCPCS:J9145)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, rituximab, 10 mg (HCPCS:J9312)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, octreotide, depot form for intramuscular injection, 1 mg (HCPCS:J2353)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, bortezomib, not otherwise specified, 0.1 mg (HCPCS:J9044)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Unclassified drugs (HCPCS:J3490)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of pneumococcal vaccine (HCPCS:G0009)
• Vincristine sulfate, 1 mg (HCPCS:J9370)
• Pneumococcal vaccine, 23-valent (HCPCS:90732)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Injection of drug or substance into vein (HCPCS:96374)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Influenza vaccine split virus, preservative free (HCPCS:90662)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0220)

The enumeration date for this NPI number is 8/21/2007 and was last updated on 8/21/2007.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: